Review of clinical trials confirms efficacy of EGb 761®
A systematic review of 9 placebo-controlled clinical trials with 946 patients confirmed the efficacy of Ginkgo biloba extract EGb 761® (active ingredient of e.g. Tebonin® and Tebokan®) in mild cognitive impairment (mild neurocognitive impairment / MCI).
A good effect of EGb 761® was shown in 8 of the 9 studies, among others in (neuropsychological) tests on brain performance. Significant effects were demonstrated in particular in the cognitive areas of memory, information processing, attention as well as planning and mental flexibility. In 3 of the 9 studies, neuropsychiatric symptoms such as anxiety or depression were examined and improved in all 3 studies by taking EGb 761®.
This summary of study results underlines that EGb 761® noticeably alleviates even mild cognitive deficits and is well tolerated. Due to the high number of people affected, this area of application is very important and the proof of efficacy is therefore particularly valuable.
Original publication: Hort J, Duning T, Hoerr R. Ginkgo biloba Extract EGb 761 in the Treatment of Patients with Mild Neurocognitive Impairment: A Systematic Review. Neuropsychiatr Dis Treat. 2023;19:647-660; doi 10.2147/NDT.S401231.